Hot News:(28 Apr 2022)
A promising combination therapy for triple-negative breast cancer
Researchers at Baylor College of Medicine and collaborating institutions have identified a combination therapy for treating triple-negative breast cancer (TNBC) that results in durable tumour regression in an animal model of the condition.
The combination therapy attacked the tumour on two fronts. On one side, the chemotherapy drug cyclophosphamide eliminated tumour cells, while on the other front, another drug inhibited tumour-associated cells called macrophages, which block the body’s immune response against the tumour.
